Intra-Cellular Therapies Financial Statements (ITCI)
|
|
|
|
Report date
|
|
|
02.03.2020 |
25.02.2021 |
01.03.2022 |
01.03.2023 |
22.02.2024 |
|
30.10.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
0.061 |
22.5 |
81.7 |
249.1 |
464.4 |
|
612.9 |
|
Operating Income, bln rub |
|
|
-154.0 |
-231.2 |
-285.7 |
-263.6 |
-159.4 |
|
-121.6 |
|
EBITDA, bln rub |
? |
|
-153.5 |
-230.7 |
-285.2 |
-263.0 |
-158.9 |
|
-121.2 |
|
Net profit, bln rub |
? |
|
-147.7 |
-227.0 |
-284.1 |
-256.3 |
-139.7 |
|
-86.4 |
|
|
OCF, bln rub |
? |
|
-128.0 |
-230.1 |
-259.5 |
-270.2 |
-124.2 |
|
-62.2 |
|
CAPEX, bln rub |
? |
|
0.700 |
0.267 |
0.326 |
0.778 |
0.269 |
|
0.750 |
|
FCF, bln rub |
? |
|
-128.7 |
-230.3 |
-259.9 |
-271.0 |
-124.5 |
|
-62.9 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
154.1 |
251.9 |
359.4 |
492.3 |
590.0 |
|
687.3 |
|
Cost of production, bln rub |
|
|
0.477 |
1.90 |
8.03 |
20.4 |
33.7 |
|
47.3 |
|
R&D, bln rub |
|
|
89.1 |
65.8 |
88.8 |
134.7 |
180.1 |
|
216.6 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.000 |
7.38 |
0.000 |
|
4.35 |
|
|
Assets, bln rub |
|
|
251.2 |
717.3 |
489.9 |
754.8 |
728.3 |
|
1 324 |
|
Net Assets, bln rub |
? |
|
195.0 |
656.9 |
417.9 |
656.1 |
591.4 |
|
1 145 |
|
Debt, bln rub |
|
|
23.1 |
29.1 |
25.4 |
20.0 |
16.9 |
|
17.7 |
|
Cash, bln rub |
|
|
224.0 |
657.4 |
412.3 |
591.9 |
497.9 |
|
1 007 |
|
Net debt, bln rub |
|
|
-200.9 |
-628.3 |
-386.9 |
-571.9 |
-481.0 |
|
-988.9 |
|
|
Ordinary share price, rub |
|
|
34.3 |
31.8 |
52.3 |
52.9 |
71.6 |
|
52.3 |
|
Number of ordinary shares, mln |
|
|
55.2 |
70.4 |
81.3 |
94.0 |
95.9 |
|
105.8 |
|
|
Market cap, bln rub |
|
|
1 893 |
2 238 |
4 253 |
4 977 |
6 867 |
|
5 536 |
|
EV, bln rub |
? |
|
1 693 |
1 609 |
3 866 |
4 405 |
6 386 |
|
4 547 |
|
Book value, bln rub |
|
|
195 |
657 |
418 |
656 |
591 |
|
1 145 |
|
|
EPS, rub |
? |
|
-2.68 |
-3.23 |
-3.50 |
-2.72 |
-1.46 |
|
-0.82 |
|
FCF/share, rub |
|
|
-2.33 |
-3.27 |
-3.20 |
-2.88 |
-1.30 |
|
-0.59 |
|
BV/share, rub |
|
|
3.53 |
9.34 |
5.14 |
6.98 |
6.17 |
|
10.8 |
|
|
EBITDA margin, % |
? |
|
-253 303% |
-1 024% |
-349.0% |
-105.6% |
-34.2% |
|
-19.8% |
|
Net margin, % |
? |
|
-243 714% |
-1 008% |
-347.7% |
-102.9% |
-30.1% |
|
-14.1% |
|
FCF yield, % |
? |
|
-6.80% |
-10.3% |
-6.11% |
-5.44% |
-1.81% |
|
-1.14% |
|
ROE, % |
? |
|
-75.8% |
-34.6% |
-68.0% |
-39.1% |
-23.6% |
|
-7.54% |
|
ROA, % |
? |
|
-58.8% |
-31.6% |
-58.0% |
-34.0% |
-19.2% |
|
-6.52% |
|
|
P/E |
? |
|
-12.8 |
-9.86 |
-15.0 |
-19.4 |
-49.2 |
|
-64.1 |
|
P/FCF |
|
|
-14.7 |
-9.71 |
-16.4 |
-18.4 |
-55.2 |
|
-88.0 |
|
P/S |
? |
|
31 238 |
99.3 |
52.0 |
20.0 |
14.8 |
|
9.03 |
|
P/BV |
? |
|
9.71 |
3.41 |
10.2 |
7.59 |
11.6 |
|
4.84 |
|
EV/EBITDA |
? |
|
-11.0 |
-6.98 |
-13.6 |
-16.8 |
-40.2 |
|
-37.5 |
|
Debt/EBITDA |
|
|
1.31 |
2.72 |
1.36 |
2.17 |
3.03 |
|
8.16 |
|
|
R&D/CAPEX, % |
|
|
12 725% |
24 663% |
27 275% |
17 316% |
66 967% |
|
28 881% |
|
|
CAPEX/Revenue, % |
|
|
1 156% |
1.18% |
0.40% |
0.31% |
0.06% |
|
0.12% |
|
| Intra-Cellular Therapies shareholders |
